Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flibanserin Open-label Extension for HSDD
NCT01103362Phase 3Terminated
- Sponsor
- Sprout Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of flibanserin in hypoactive sexual desire disorder (HSDD), sponsored by Sprout Pharmaceuticals. Primary endpoint: Frequency of Adverse Events at 28 weeks. Started Apr 2010; status: terminated.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT01103362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103362.